Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NRAS | P01111 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 12/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31739608 | 1.00 | NRAS (0.40) | NRASFLT3FYNPDE4DCSNK2A1 | |
| SCHEMBL30698355 | 0.84 | NRAS (0.36) | NRASFLT3FYNPDE4DDYRK3 | |
| SCHEMBL24542495 | 0.81 | FLT3 (0.42) | NRASFLT3FYNPDE4DDYRK3 | |
| SCHEMBL29682761 | 0.81 | FLT3 (0.42) | NRASFLT3FYNPDE4DDYRK3 | |
| SCHEMBL27331052 | 0.79 | FLT3 (0.42) | NRASFLT3CSNK2A1 | |
| SCHEMBL31739786 | 0.79 | NRAS (0.51) | NRASFLT3 | |
| SCHEMBL27327913 | 0.79 | NRAS (0.51) | NRASFLT3 | |
| SCHEMBL30698339 | 0.79 | FLT3 (0.42) | NRASFLT3CSNK2A1 | |
| SCHEMBL27327095 | 0.79 | FLT3 (0.42) | NRASFLT3CSNK2A1 | |
| SCHEMBL27332547 | 0.79 | NRAS (0.51) | NRASFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368648-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4540248-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023245123-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368648-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK1, IRAK2 | NRAS 371/4885FLT3 1/4885FYN 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.